From GlobeNewswire.: 2024-05-07 21:42:00

In the first quarter of 2024, ZYNLONTA® generated a net revenue of $17.8 million, with total operating costs decreasing by 25% compared to the same period in 2023. The LOTIS-7 dose escalation was successfully completed, and expansion is underway for 2L+ DLBCL. Promising Phase 2 MZL data shows encouraging results.

ADC Therapeutics reported financial results for the first quarter of 2024, highlighting progress in their hematology focus with ZYNLONTA® and advancing their solid tumor pipeline. ZYNLONTA saw sequential revenue growth in the first quarter, and the LOTIS-7 study with ZYNLONTA in combination with bispecific antibodies completed its dose escalation phase.

The Phase III confirmation study for ZYNLONTA in combination with Rituximab for 2L+ DLBCL patients, known as LOTIS-5, continues to accelerate recruitment. LOTIS-7, an open Phase 1b study combining ZYNLONTA with bispecific antibodies, showed encouraging anti-tumor activity with no dose-limiting toxicities observed.

A Phase 2 study initiated by investigators evaluated ZYNLONTA for r/r MZL and showed promising results in 15 patients, with 13 achieving a complete response and one a partial response. The study demonstrated good tolerability and safety, with two patients discontinuing treatment.

ADC Therapeutics discussed their pipeline for solid tumors, including ADCT-601 targeting AXL. The ongoing Phase 1b study is optimizing dosing for patients with pancreatic cancer and other AXL-expressing tumors, while preclinical data for ADCs targeting other markers like NaPi2b and Claudin-6 show strong anti-tumor activity.

Financially, ADC Therapeutics reported $17.8 million in net product revenue for ZYNLONTA in the first quarter of 2024. Research and development expenses decreased to $25.7 million in the same period, attributed to reduced investments in Camidanlumab Tesirin. Cash and cash equivalents totaled $234.3 million as of March 31, 2024.

Looking ahead, ADC Therapeutics aims to achieve commercial brand profitability for ZYNLONTA in 2024 and expects to complete recruitment for key studies like LOTIS-5 and LOTIS-7 by the end of the year. Updates on pipeline candidates and financial performance are anticipated in the coming quarters.



Read more at GlobeNewswire.:: ADC Therapeutics veröffentlicht die Finanzergebnisse des